Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
The day's biggest deal came from pharma. VTRS announced it will acquire PCRX in a move to build out its non-opioid painkiller portfolio. The buyout is the clearest sign yet that generic drug makers are looking beyond their core business to find growth. Pacira's shares moved sharply on the news.
GFS secured a $2 billion deal with TSMC to expand AI chip packaging inside the United States. The agreement underlines how semiconductor supply chains are being reshaped closer to home. It also feeds directly into the two-way options flow that has dominated chip names this week. sits up 281% year-to-date and is drawing the heaviest volume on both the bull and bear side. and show the same split. AMD's RSI has hit 70.7, touching overbought territory ahead of its Q3 print. Japan's machine tool orders, up 65% year-on-year in August, point to sustained industrial capex. That kind of real-economy data gives bulls in semis something to lean on.
The Financial Times reported today that OpenAI's annualised revenues are $20 billion below what was previously signalled. MSFT has a deep financial tie to OpenAI. The shortfall raises questions about the pace of AI monetisation across the sector.
DAL kicks off Q3 season tomorrow. The bigger wave arrives mid-week. BAC, JNJ, and UNH all report between Tuesday and Wednesday. Medicare Advantage penetration reached 51.1% in June 2026, the highest on record, per ORTEX alt data. That structural shift is a direct tailwind for managed care going into UnitedHealth's print.
Short sellers are watching housing. LEN short interest rose to 14.1% of free float this week, up 3.8 points, as elevated mortgage rates keep the bears active in homebuilders.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
